Registry-based clinical research in prostate cancer is critical to advancing quality in disease management and ultimately in reducing disparate outcomes of this disease in those affected. A critical need exists to develop a Health Insurance Portability and Accountability Act (HIPAA)-compliant Registry that comprise predominantly of African American patients since these men are disproportionately impacted by this condition. High quality prospective data on long-term outcomes have been lacking in prostate cancer for African American men and unfortunately most current and past registries have only a small percentage of these men enrolled. Without a registry that contains a large proportion of African American men with prostate cancer, many basic aspects of this disease in this population will continue to be poorly understood, including the natural history, treatment practice trends, and quality outcomes. Moreover, the creation of a collaborative partnership among urologists can increase enrollment of African American men with prostate cancer into all phases of clinical trials. A longitudinal, observational registry provides an unparalleled opportunity for high quality research to support evidence-based care. Thus, the overall aims of the SCOPE Registry are to determine ways to improve healthcare outcomes of men with prostate cancer and to eliminate prostate cancer disparities.